No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US Stock MarketDetailed Quotes
GANX Gain Therapeutics
- 2.180
- +0.420+23.86%
Close Dec 30 16:00 ET
- 2.300
- +0.120+5.50%
Post 19:40 ET
57.82MMarket Cap-2.04P/E (TTM)
2.190High1.840Low531.27KVolume1.860Open1.760Pre Close1.06MTurnover2.11%Turnover RatioLossP/E (Static)26.53MShares5.33052wk High6.49P/B54.99MFloat Cap0.89052wk Low--Dividend TTM25.22MShs Float17.930Historical High--Div YieldTTM19.89%Amplitude0.890Historical Low2.003Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Gain Therapeutics' GT-02287 Study to Deliver Positive Findings, Says Roth MKM
Roth MKM Maintains Gain Therapeutics(GANX.US) With Buy Rating, Maintains Target Price $7
Gain Therapeutics Says Australia Approves Start of Phase 1b Parkinson's Disease Study
Express News | Gain Therapeutics Inc - Enrollment Expected to Complete in Spring 2025, Data Expected Mid-2025
Gain Therapeutics Initiates Phase 1b Clinical Trial of Lead Candidate GT-02287 in People With GBA1 and Idiopathic Parkinson's Disease
Express News | Gain Therapeutics Initiates Phase 1B Clinical Trial of Lead Candidate GT-02287 in People With Gba1 and Idiopathic Parkinson’s Disease
Heat List
US
Overall
Symbol
Price
% Chg
No Data
